Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Cardiol Therapeutics (NASDAQ:CRDL) and raises the price target from $6 to $8.
May 23, 2024 | 11:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Cardiol Therapeutics and raises the price target from $6 to $8.
The raised price target from $6 to $8 and the maintained Buy rating by Canaccord Genuity is likely to positively impact investor sentiment and drive short-term price appreciation for Cardiol Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100